Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer.

Buck, Emanuel; Sprick, Martin; Gaida, Matthias M; Grüllich, Carsten; Weber, Tim Frederik; Herpel, Esther; Bruckner, Thomas; Koschny, Ronald

Buck, Emanuel; Sprick, Martin; Gaida, Matthias M; Grüllich, Carsten; Weber, Tim Frederik; Herpel, Esther; Bruckner, Thomas; Koschny, Ronald.

Afiliación

Buck E; Department of Gastroenterology, University Hospital Heidelberg, D-69120 Heidelberg, Germany.
Sprick M; HI-STEM gGmbH/German Cancer Research Center Heidelberg (MRS), D-69120 Heidelberg, Germany.
Gaida MM; Department of Pathology, National Center for Tumor Diseases, University Hospital Heidelberg, D-69120 Heidelberg, Germany.
Grüllich C; Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, D-69120 Heidelberg, Germany.
Weber TF; Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, D-69120 Heidelberg, Germany.
Herpel E; Department of Pathology, National Center for Tumor Diseases, University Hospital Heidelberg, D-69120 Heidelberg, Germany.
Bruckner T; Institute for Medical Biometry and Informatics, University of Heidelberg, D-69120 Heidelberg, Germany.
Koschny R; Department of Gastroenterology, University Hospital Heidelberg, D-69120 Heidelberg, Germany.

Oncol Lett ; 17(4): 3890-3898, 2019 Apr.

Article en En | MEDLINE | ID: mdl-30881507

Palabras clave

RECIST; colorectal adenoma; colorectal cancer; cytochrome P450 3A5; immunohistochemistry; irinotecan; resistance

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncol Lett Año: 2019 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Grecia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google